Navigation Links
BioElectronics Corporation's New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
Date:4/9/2008

FREDERICK, Md., April 9, 2008 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the company will start airing a new commercial for its ActiPatch (TM) technology on Bloomberg Television, April 14, 2008. The company has initiated an advertising contract that calls for the informational commercial to run for the next two weeks, and will reach millions of viewers daily. CEO Andrew Whelan comments, "This is a new initiative for BioElectronics Corporation and we are excited that this commercial will inform consumers, physicians, and distributors about our ActiPatch(TM) products. This national advertisement should help us reach a new level in both product and brand awareness."

The new bio-electronic super-bandage has produced significant rapid healing results in trials and has already received regulatory clearance by the FDA for the treatment of edema following blepharoplasty.

"ActiPatch (TM)" is very thin, easily applied and comfortable to wear on an injured area. The patch effectively minimizes pain and swelling. Physicians are so impressed with the power of the patch that they are providing it to their patients for uses beyond plastic surgery recovery. Trials are ongoing in multiple areas.

The new ActiPatch(TM) retail product line targets five common conditions that affect hundreds of millions of people throughout the world: 1) Back pain, 2) Foot and ankle pain, including ankle sprains and plantar fasciitis, 3) Knee pain, 4) Arm and wrist pain, including carpal tunnel and tennis elbow. BioElectronics has planned an aggressive retail introduction of these products for locations outside of the United States where regulatory clearance has been received. Distribution is expected in Canada, Italy, Netherlands, Australia, Mexico, United Kingdom, the Middle East, and other countries over the next few months.

About BioElectronics

BioElectronics Corporation is the maker of the ActiPatch(TM).
'/>"/>

SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. BioElectronics Corporation Receives 2007 Economic Development Innovator of the Year Award
2. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
3. BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11
4. Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org
5. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
6. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
7. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
8. OmniGuide Begins European Commercialization
9. Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success
10. Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care
11. Anesiva to Unveil Zingo(TM) Commercialization Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...LE, N.Y., Nov. 21 A prestigious gr...roviders will gather in Williamsburg, VA on March ...ctical, clinical information on cutting-edge thera... innovative research advances that impact patient ...d registration information is available at www.bi...
(Date:11/21/2008)...RK Tobacco use is more prevalent and smoking ce...eficit Hyperactivity Disorder (A.D.H.D.) In a stu...vity symptoms, those who exhibited elevated hypera...on, showed lower quit rates after 8 weeks than tho...t the A.D.H.D. symptoms. The study, now available...
(Date:11/21/2008)...S, Nov. 21 Three Minnesotans who s...during a special on-ice presentation at,the Minne...enter. The winners,were participants in The QuitC...earWay Minnesota(SM) and QUITPLAN(R) Services. , ...n cash, while two runners-up,will get $1,000 gift...
(Date:11/21/2008)...S, Nov. 21 In a recent announcemen... the Sales and Use Tax to include,"luxury" items ...e an increase,in animal shelter overpopulation. ...ning forces and urging all pet owners to take acti... to stop this tax. , "Our companion animals...
Breaking Medicine News(10 mins):Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2Health News:Lucky Quitters to Receive Big Money in Stop-Smoking Contest 2Health News:A Recommended Sales and Use Tax Proposed by Governor Schwarzenegger Will Tax Veterinary Services, Says Social Compassion in Legislation 2Health News:A Recommended Sales and Use Tax Proposed by Governor Schwarzenegger Will Tax Veterinary Services, Says Social Compassion in Legislation 3
...s have called on the medical profession to push Go...tween Indigenous and non-Indigenous Australians . ...ia, Dr Mark Wenitong, President of the Australian ...his co-authors from the National Aboriginal Commun...
... to reduce the risk of diabetes in the Indigenous ...byn McDermott, Pro-vice Chancellor of the Division...tralia, shows that while clinical care of adults w...ed, more Indigenous Australians are developing the...
...oxidant coenzyme Q10 appear to increase blood leve...s with Parkinsons disease , but does not improve ... Parkinsons disease is a neurodegenerative disorde...culty with walking or other movements. The biologi...
...lves in the mouth like a popular breath-freshener ...e to infants in impoverished areas. The innovativ...ins undergraduate biomedical engineering students....seven-student team fabricated a thin film that sho...
Other Medicine News:Health News:Coenzyme Q10 Does Not Improve Parkinsons Disease Symptoms 2Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 2Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 3
(Date:11/19/2008)... Roche- , , MONTVALE, N.J., Nov. 19 /PRNews...asdaq: MEMY ) today announced that it has achiev...487/MEM 3454, its lead alpha-7 nicotinic receptor ...chizophrenia (CIAS). The Company has randomized 2...0 million payment from its partner Roche. Memory ...
(Date:11/18/2008)...re-USNewswire/ -- Forty-two leading U. S. scientis... forum to consider cutting-edge innovations that m...nomy from outbreaks of dangerous zoonotic diseases...g those innovations: , , , , A ...t detects highly contagious and dangerous zoonotic...
(Date:11/13/2008)...l Supplements Prior to Surgery, ARLINGTON HEIGHTS...ying,malnutrition before surgery in massive weight...icantly decrease surgical complications, accelerat...tient energy levels,according to a study in the D...y(R), the official medical journal of the American...
(Date:11/12/2008)...el, November 12 Surgeons,at the Un... that,patient-specific CTA data can be converted t...bionix US) with high face validity. The surgeons,"...operative flow,increased patient safety and effic...ve and fluoroscopy time and the amount of contrast...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 1Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 2Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 3Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 4Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 1Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 2Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 3Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 4Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 5Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 6Mirixa Debuts RxFYI a Free Pharmacy Published Health eNewsletter Building Patient Loyalty and Generating Revenue 3893 1Mirixa Debuts RxFYI a Free Pharmacy Published Health eNewsletter Building Patient Loyalty and Generating Revenue 3893 2ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 1ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 2ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 3ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 4ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 5ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 6ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 7
...SINESS WIRE)--Jun 5, 2007 - First-in-human results...mClone Systems,Incorporated (NASDAQ: IMCL) and tar... receptor), were presented at the annual,meeting o...cago.,The IGF-IR is expressed on the cell surface ...ead to tumor cell growth and,proliferation, and in...
...ss.--(BUSINESS WIRE)--Jun 5, 2007 - Elixir,Pharmac...ta,confirming ghrelin antagonism as a potential me...ight and managing blood glucose. The,data were pre...crine Society,s 89th Annual Meeting, being held in...ment of drugs to treat and,prevent metabolic disea...
Other Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4
...ghput immunoassay system built around the many pos...important addition of Logic Driven Incubation (LDI...for optimal performance with the fastest possible ...ys such as the cardiac biomarkers and HCG to be ru...
For The Detection Of Serum C-Peptide Levels.,Clinical Uses Of C-Peptide Measurement:, Evaluating patients with fasting hypoglycemia , Assisting in the classification of diabetes mellitus , D
Measles IgG ELISA test system is designed for the qualitative detection of IgG antibodies to Measles (Rubeola) virus in human serum, and is for in vitro diagnostic use.
Inquire
Medicine Products: